NEO Earnings Date: Feb 16, 2027 (Estimated) — NeoGenomics, Inc.
NASDAQ · Healthcare · Diagnostics & Research
Updated
When is NEO's next earnings date?
NeoGenomics, Inc. (NEO) is expected to report Q4 2026 earnings on Tuesday, February 16, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.05 on revenue of $209.7M.
How did NEO do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), NeoGenomics, Inc. posted EPS of $0.07 versus the $0.06 estimate, a beat of 26.2%. Revenue was $209.3M against a $206.7M estimate. The stock's 1-day post-earnings move was +4.2%.
How much does NEO stock move after earnings?
NEO beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.7% (up or down) in the day after earnings.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in providing cancer-focused diagnostic and testing services through an extensive network of laboratories located across the United States, Europe, and Asia. The company operates through two distinct divisions: Clinical Services and Pharma Services. Its comprehensive offerings cater to a diverse clientele, including hospitals, reference laboratories, pathologists, oncologists, clinicians, pharmaceutical companies, and researchers. NeoGenomics' advanced testing capabilities encompass cytogenetics, which examines normal and abnormal chromosomes in relation to disease; fluorescence in-situ hybridization (FISH) for detecting and pinpointing specific DNA sequences and genes on chromosomes; and flow cytometry, used to measure cell population characteristics. Additionally, the company provides immunohistochemistry and digital imaging services, enabling the localization of cellular proteins in tissue sections, visualization of scanned slides, and quantitative analysis. Molecular testing, focusing on DNA/RNA analysis and gene structure/function, is also a key offering, alongside morphologic analysis where pathologists microscopically diagnose cells. Beyond clinical diagnostics, NeoGenomics supports pharmaceutical clients' oncology programs from discovery to commercialization and acts as a reference laboratory for anatomic pathology testing. The company, founded in 2001 and headquartered in Fort Myers, Florida, also maintains a strategic alliance and laboratory services agreement with Inivata Limited.
🤖 AI Earnings Analysis
NeoGenomics posted a modestly positive diagnostics quarter: revenue rose 11% to $209M and EPS doubled to $0.07, beating estimates, but a $27M operating loss and reaffirmed $802M–$806M revenue guidance temper momentum.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | 0.06 | 0.07 | +26.22% | $209.3M | ✅ Beat | +4.17% | — | — |
| 2026-08-11 | Q2 2026 | 0.38 | 0.51 | +34.21% | $205.7M | ✅ Beat | -0.60% | -2.83% | +6.19% |
| 2026-07-28 | 0.03 | 0.05 | — | $201.7M | ✅ Beat | +16.21% | +20.55% | +27.78% | |
| 2026-05-12 | Q1 2026 | 0.14 | 0.34 | +142.86% | $155.0M | ✅ Beat | +1.04% | -3.35% | +30.25% |
| 2026-02-17 | Q4 2025 | 0.01 | 0.06 | +500.00% | $190.2M | ✅ Beat | +0.53% | -12.39% | -27.33% |
| 2025-10-28 | Q3 2025 | -0.01 | 0.03 | +400.00% | $187.8M | ✅ Beat | -2.36% | -3.74% | +21.46% |
| 2025-07-29 | Q2 2025 | -0.01 | 0.03 | +400.00% | $181.3M | ✅ Beat | -18.73% | -12.23% | +3.72% |
| 2025-04-29 | Q1 2025 | -0.01 | 0.00 | +100.00% | $168.0M | ✅ Beat | -34.00% | -21.36% | -25.58% |
Showing last 8 quarters.